SEC Form 4 · accession 0001019056-17-000286

Aptevo Therapeutics Inc. · APVO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Medical Officer and SVP

Period of report

Mar 1, 2017

Accepted (ET)

Mar 13, 2017 · 9:05 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001671584

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 1, 2017	M	16,269	—	A	45,894	D
Common Stock	Mar 1, 2017	F	5,312	$2.02	D	40,582	D
Common Stock^F1	Mar 9, 2017	M	13,902	—	A	54,484	D
Common Stock	Mar 9, 2017	F	3,678	$1.80	D	50,806	D
Common Stock^F1	Mar 10, 2017	M	24,836	—	A	75,642	D
Common Stock	Mar 10, 2017	F	6,570	$1.78	D	69,072	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Unit^F1,F2	—	Mar 1, 2017	M	16,269	D	—	—	Common Stock	16,269	190,672	D
Restricted Stock Unit^F1,F3	—	Mar 9, 2017	M	13,902	D	—	—	Common Stock	13,902	176,770	D
Restricted Stock Unit^F1,F4	—	Mar 10, 2017	M	24,836	D	—	—	Common Stock	24,836	151,934	D

F1Each RSU converts into the Issuer's common stock on a one-for-one basis.
F2The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 1, 2016. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments on the anniversary of the grant date.
F3The RSUs were originally issued by Emergent on March 10, 2015 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs vest as follows: 13,902 on March 9, 2017 and 13,892 on March 9, 2018.
F4The RSUs were originally issued by Emergent on March 11, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on March 10, 2017.